Mazama Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Mazama Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,221	Closed	-$49K	–	52
2015 Q4	$49K	Buy	2,221 +880	+66%	+$22.2K	0.01%	214
2015 Q3	$32K	Buy	+1,341	New	+$84.2K	0.01%	226
2015 Q2	–	Sell	-202	Closed	-$19K	–	292
2015 Q1	$19K	Sell	202 -528	-72%	-$34.1K	﹤0.01%	256
2014 Q4	$30K	Sell	730 -2,542	-78%	-$77.8K	0.01%	248
2014 Q3	$80K	Buy	3,272 +1,993	+156%	+$31.7K	0.02%	206
2014 Q2	$20K	Hold	1,279	–	–	0.01%	251
2014 Q1	$19K	Sell	1,279 -50,638	-98%	-$786K	0.02%	218
2013 Q4	$713K	Sell	51,917 -50,707	-49%	-$738K	0.35%	114
2013 Q3	$1.94M	Sell	102,624 -48,998	-32%	-$823K	1.06%	27
2013 Q2	$2.14M	Buy	+151,622	New	+$2.15M	1.33%	19

Other funds holding ESPR

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Mazama Capital Management's ESPR Position: Q1 2016 in Review

Mazama Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2016, closing a stake of 2,221 shares — an estimated $49K sold.

Mazama Capital Management first reported a position in ESPR in Q2 2013 and held it in 10 quarters. The position peaked at $2.14M in Q2 2013. 109 funds tracked by Wall St. Rank hold ESPR as of Q1 2016.

Mazama Capital Management reported no remaining Esperion Therapeutics position as of Q1 2016 after selling out during the quarter.
Mazama Capital Management sold 2,221 Esperion Therapeutics shares in Q1 2016, an estimated $49K.
Mazama Capital Management first reported a position in Esperion Therapeutics in Q2 2013 and held it in 10 quarters.
Mazama Capital Management's Esperion Therapeutics position peaked at $2.14M in Q2 2013.
109 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.